Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Neoplasms × Ketamine × Clear all

Phase

Phase 3 5 Phase 2 4 Phase NA 2 Phase EARLY_PHASE1 2 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pain, Postoperative 2 Depression 2 Agnosia 2 Prostatic Neoplasms 1 Postoperative Analgesia 1 Neoplasms 1 Breast Neoplasms 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 4 gamma-Globulins 3 Standard of Care 3 Oxaliplatin 3 Melatonin 3 Gemcitabine 3 Fluorouracil 3 Drug Therapy 3 Ciprofloxacin 3 Capecitabine 3 pertuzumab 2 entrectinib 2 cobimetinib 2 capmatinib 2 atezolizumab 2 alectinib 2 Water 2 Vemurafenib 2 Trastuzumab 2 Sirolimus 2 Saline Solution 2 Pemetrexed 2 Methylphenidate 2 Lidocaine 2 Leucovorin 2 Immunoglobulins, Intravenous 2 Docetaxel 2 Dexmedetomidine 2 Cisplatin 2 Carboplatin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02783430 2025-12-16

KETAPAL

University Hospital, Lille

Phase 2/3 Completed

Depression, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡